Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | GRM5 | P41594 | 16/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136590 | 0.81 | EPHX2 (0.55) | EPHX2NPC1TSHR | |
| SCHEMBL21163198 | 0.76 | GRM5 (0.47) | GRM5 | |
| SCHEMBL21163195 | 0.71 | GRM5 (0.47) | GRM5 | |
| SCHEMBL17069026 | 0.70 | EPHX2 (0.58) | EPHX2GRM5 | |
| SCHEMBL24467452 | 0.68 | GRM5 (0.35) | GRM5 | |
| SCHEMBL17069024 | 0.66 | EPHX2 (0.53) | EPHX2TSHR | |
| SCHEMBL18471516 | 0.65 | SMN1; SMN2 (0.42) | EPHX2NPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL14072034 | 0.65 | ALDH1A1 (0.47) | EPHX2NPC1TSHR | |
| SCHEMBL3973846 | 0.64 | SCD5 (0.63) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22893351 | 0.63 | MAPT (0.59) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2025-09-11 | — | — | US | claimed |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2024-09-05 | — | — | US | claimed |
| CN-114716390-A | Compositions and methods for treating and/or preventing necrosis of cells or tissue | ELA制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2018-11-01 | — | — | US | claimed |
| EP-3280401-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162870-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | NATHAN ILANA (IL) | 2016-10-13 | — | — | WO | claimed |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2025-09-11 | — | — | US | disclosed |
| JP-2024122988-A | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | イーエルエイ ファーマ リミテッド | 2024-09-10 | — | — | JP | disclosed |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2024-09-05 | — | — | US | disclosed |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | Ela Pharma Ltd (IL) | 2024-04-02 | — | — | US | disclosed |
| CN-114716390-A | Compositions and methods for treating and/or preventing necrosis of cells or tissue | ELA制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4005569-A2 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2022-06-01 | — | — | EP | disclosed |
| EP-4005569-A2 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2022-06-01 | — | — | EP | disclosed |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2021-10-07 | — | — | US | disclosed |
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | ELA PHARMA LTD. (IL) | 2021-04-06 | — | — | US | disclosed |
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | ELA PHARMA LTD. (IL) | 2021-04-06 | — | — | US | disclosed |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2018-11-01 | — | — | US | disclosed |
| EP-3280401-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016162870-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | NATHAN ILANA (IL) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016162870-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | NATHAN ILANA (IL) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSV, CTSA | EPHX2 1895/4885GRM5 4812/4885NPC1 2878/4885 |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | EPHX2 1660/4885GRM5 4860/4885NPC1 2334/4885 |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | EPHX2 1660/4885GRM5 4860/4885NPC1 2334/4885 |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSA, CPA1 | EPHX2 2121/4885GRM5 4840/4885NPC1 1581/4885 |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | EPHX2 1660/4885GRM5 4860/4885NPC1 2334/4885 |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CTSA, CTSG, CELA1 | EPHX2 1407/4885GRM5 4871/4885NPC1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.